Newer products like cardiology drug Repatha and immunology drug Tezspire (approved in December 2021) are poised to be top products by 2030, in addition to Lumakras (approved in May 2021).

In the past 21 months, Amgen's recently approved products in the U.S. included IMLYGIC (in October 2015), Repatha ( September 2015), Corlanor (April 2015), and BLINCYTO (December 2014).

Topline The Federal Trade Commission announced Friday it had reached a settlement with Amgen Inc. over the biopharmaceutical firm’s $27.8 billion acquisition of Horizon Therapeutics, after the ...

Much of the boost can be attributed to sales of products acquired in Amgen’s $27.8 billion buyout of Horizon Therapeutics, which was completed early in the fourth quarter of last year. Assets ...

WASHINGTON—The Federal Trade Commission said Friday it had agreed to end its legal challenge of drugmaker Amgen ’s AMGN 3.32% $27.8 billion deal to buy Horizon Therapeutics, averting a trial ...

Amgen Inc has agreed not to quickly close on its $27.8 billion acquisition of Horizon Therapeutics after the U.S. Federal Trade Commission (FTC) filed suit to block the deal.

“In our opinion, Amgen’s fundamentals have never been stronger,” said Wang, who has a $100 12-month target price for Amgen shares, which were trading around $80 on Dec. 6.

In a news release Friday, the US antitrust regulator said it accepted a proposal from Amgen that would allow the $27.8 billion deal under multiple conditions, including that Amgen would not ...

Last Updated: Aug. 29, 2023 at 3:22 p.m. ET First Published: Aug. 29, 2023 at 7:50 a.m. ET ...

Amgen Inc. said it had agreed to sell two of its smaller drugs and license a third to Swedish drugmaker Biovitrum AB in a deal valued at $130 million.